Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women

Menopause

Volumn 16, Issue 5, 2009, Pages 923-931

  Labrie, Fernand ^a,b   Archer, David ^c   Bouchard, Céline ^d   Fortier, Michel ^d   Cusan, Leonello ^a   Gomez, José Luis ^a   Girard, Ginette ^e   Baron, Mira ^f   Ayotte, Normand ^g   Moreau, Michèle ^h   Dubé, Robert ^a   Côté, Isabelle ^b   Labrie, Claude ^a,b   Lavoie, Lyne ^b   Berger, Louise ^b   Gilbert, Lucy ⁱ   Martel, Céline ^b   Baiser, John ^j  

^a LAVAL UNIVERSITY   (Canada)

^b Endoceutics Inc   (Canada)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d Clinique de Recherche en Sante des Femmes   (Canada)

^e Diex Recherche Inc   (Canada)

^f Rapid Medical Research   (United States)

^g Clinique Gynecologique   (Canada)

^h Centre for Building Studies   (Canada)

ⁱ ROYAL VICTORIA HOSPITAL   (Canada)

^j Veristat Inc   (United States)

more..

Author keywords

Dehydroepiandrosterone; Libido; Postmenopause; Prasterone; Sexual dysfunction

Indexed keywords

PLACEBO; PRASTERONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPAREUNIA; FEMALE; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; ORGASM; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; VAGINA ATROPHY; VAGINAL DRYNESS;

ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ATROPHY; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIBIDO; MIDDLE AGED; POSTMENOPAUSE; QUESTIONNAIRES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; VAGINA;

EID: 72249101980     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31819e85c6     Document Type: Article

References (76)

1. Béjin. A. Sexual pleasures, dysfunctions, fantasies, and satisfaction, In: Spira A, Bajos N, eds. Sexual Behaviour and AIDS. Aldershot, England: Avebury; 1994:163-171.
2. McHorney CA, Rust J, Golombok S, et al. Profile of Female Sexual Function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause 2004; 11:474-483. (Pubitemid 40372094)
3. Kontula O, Haavio-Mannila E. Sexual Pleasures. Enhancement of Sex Life in Finland, 1971-1992. Aldershot, England: Dartmouth, 1995.
4. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual, problems in younger women, after breast cancer surgery. J Clin Oncol 2006;24:2815-2821. (Pubitemid 46655597)
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544. (Pubitemid 29081307)
6. Bancroft J, Janssen E, Strong D, Carnes L, Vukadinovic Z, Long JS. Sexual risk-taking in gay men: the relevance of sexual arousability, mood, and sensation seeking. Arch Sex Behav 2003;32:555-572. (Pubitemid 38076607)
7. Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fértil Steril 2002;77:S89-S93.
8. Nathorst-Boos J, von Schoultz B. Psychological, reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992;34:97-101.
9. American. Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
10. Basson R, Althof S, Davis S, et al. Summary of the recommendations on sexual dysfunctions in women Berl Munch Tierarztl Wochenschr 2004;1:24-34. (Pubitemid 40424663)
11. Sherwin BB, Gelfand MM, Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160.
12. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49:397-409.
13. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal, women. Climacteric 2008;11:181-191.
14. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-236.
15. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-1352. (Pubitemid 36687880)
16. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women, Arch Gen Psychiatry 2000;57:149-153; discussion 155-156.
17. Tuiten A, van Honk. J, Verbaten R, Laan E, Everaerd W, Stam H. Can sublingual testosterone increase subjective and physiological measures of laboratory-induced sexual, arousal? Arch Gen Psychiatry 2002;59: 465-466. (Pubitemid 34477683)
18. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women, Menopause 2003;10:390-398.
19. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women, dissatisfied with, estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med 1998; 43:847-856. (Pubitemid 28481075)
20. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006; 13:770-779.
21. Davis SR, Tran J. Testosterone influences libido and well being in women. Trends Endocrinol Metab 2001;12:33-37. (Pubitemid 33713184)
22. Hulter B, Lundberg PO. Sexual function in women with hypothalamopituitary disorders. Arch Sex Behav 1994;23:171-183. (Pubitemid 24110550)
23. Basson R. Hormones and sexuality: current complexities and future directions. Maturitas 2007;57:66-70. (Pubitemid 46602895)
24. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin, on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1.990; 70:1124-1131.
25. van Anders SM, Hamilton LD, Schmidt N, Watson. NV. Associations between, testosterone secretion and sexual activity in women, Horm Behav 2007;51:477-482. (Pubitemid 46550424)
26. Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fértil Steril 2008;90:129-140.
27. van Anders SM, Hampson E. Waist-to-hip ratio is positively associated with bioavailable testosterone but negatively associated with sexual, desire in healthy premenopausal women. Psychosom Med 2005;67:246-250. (Pubitemid 40410960)
28. Labrie F, Bélanger A, Bélanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182-188. (Pubitemid 43766081)
29. Labrie F, Luu-The V, Bélanger A, Lin S-X, Simard J, Labrie C. Is DHEA a hormone? Starling Review. J Endocrinol 2005;187:169-196.
30. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:2243-2248.
31. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-3505. (Pubitemid 27419111)
32. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6:138-146. (Pubitemid 29266673)
33. Labrie F. Drug insight: breast cancer prevention, and tissue-targeted honnone replacement therapy. Nat Clin Pract Endocrinol Metab 2007; 3:584-593. (Pubitemid 47094559)
34. Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201-215. (Pubitemid 41096681)
35. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical, estrogen therapy on the vaginal vascularization and sexual, function in hysterectomized postmenopausal women. Menopause 2006;13:737-743. (Pubitemid 44435028)
36. Gonzalez M, Viafara G, Caba F, Molina E. Sexual function, menopause and hormone replacement therapy (HRT). Maturitas 2004;48:411-420. (Pubitemid 38993255)
37. Guay A, Munarriz R, Jacobson J, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. Int J Impot Res 2004;16:112-120. (Pubitemid 38579455)
38. Quirk F, Heiman J, Rosen R, Laan E, Smith. M, Boolell M, Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med 2002; 11:277-289. (Pubitemid 34467557)
39. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50:209-221.
40. Dupuy H. The Psychological Well-Being (PGWB) index, In: Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: LeJacq, 1984:170-183.
41. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone Prasterone, the physiological and a highly efficient treatment of vaginal atrophy. In preparation with Menopause 2009;16:907-922.
42. Labrie F, Cusan. L, Gomez JL, et al. Changes in serum DHEA and eleven, of its metabolites during 12-month percutaneous administration, of DHEA. J Steroid Biochem Mol Biol 2008; 110:1-9.
43. Labrie F, Cusan L, Gomez JL, et al, Corrigendum to: effect of intravaginal DHEA on serum. DHEA and eleven, of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008; 112:169.
44. Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal DHEA administration, In preparation with Menopause 2009;16:897-906.
45. Osbom M, Hawton K, Gath D. Sexual dysfunction among middle aged women in the community. BMJ(CHn Res Ed) 1988;296:959-962. (Pubitemid 18093430)
46. Hallstrom T. Sexuality in the climacteric. Clin Obstet Gynaecol 1977;4:227-239.
47. Hallstrom T, Samuelsson S. Changes in women's sexual desire in middle life: the longitudinal study of women in Gothenburg. Arch Sex Behav 1990;19:259-268. (Pubitemid 20207064)
48. Bancroft J, Cawood EH. Androgens and the menopause; a study of 40-60-year-old women. Clin Endocrinol (Oxf) 1996;45:577-587. (Pubitemid 26411359)
49. Avis NE, Stellate R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning? Menopause 2000;7:297-309. (Pubitemid 30679426)
50. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76: 456-460. (Pubitemid 32776534)
51. Dennerstein L, Smith AM, Morse CA, Burger HG. Sexuality and the menopause. J Psychosom Obstet Gynaecol 1994;15:59-66.
52. Leiblum SR, Koochaki. PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006;13:46-56.
53. Tiefer L. The emerging global discourse of sexual rights. J Sex Marital Ther 2002;28:439-444.
54. Tiefer L, Hall M, Tavris C. Beyond dysfunction: a new view of women's sexual problems. J Sex Marital Ther 2002;28:225-232. (Pubitemid 34202994)
55. Greenblatt RB. Androgenic therapy in women. J Clin Endocrinol 1942;2:655-666.
56. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-351. (Pubitemid 15233431)
57. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function, after oophorectomy. N Engl J Med 2000;343:682-688.
58. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589. (Pubitemid 41124151)
59. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90: 5226-5233.
60. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944-952. (Pubitemid 40571010)
61. Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women, treated with testosterone: a randomized, placebo-controlled trial. Menopause 2006;13:37-45. (Pubitemid 43755895)
62. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341:1013-1020. (Pubitemid 29451796)
63. Bilger M, Speraw S, LaFranchi SH, Hanna CE. Androgen replacement in adolescents and young women, with hypopituitarism. J Pediatr Endocrinol Metab 2005;18:355-362. (Pubitemid 40520628)
64. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione, superimposed on growth, hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial, J Clin Endocrinol Metab 2005;90:3295-3303.
65. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial, J Clin Endocrinol Metab 2002;87: 2046-2052. (Pubitemid 34525078)
66. Spark RF. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil Steril 2002;77:S19-S25.
67. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311-318.
68. Rubino S, Stomati M, Bersi C, et al. Neuroendocrine effect of a shortterm treatment with DHEA in postmenopausal women. Maturitas 1998;28:251-257. (Pubitemid 28162438)
69. Stomati. M, Monteleone P, Casarosa E, et al. Six-months oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14:342-363. (Pubitemid 30943364)
70. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704. (Pubitemid 20286072)
71. Morales AJ, Nolan JJ, Nelson JC, Yen. SS. Effects of replacement dose of dehydroepiandrosterone in. men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-1367.
72. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999;84:1527-1533.
73. Lovas K1 Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003;88:1112-1118.
74. Libe R, Barbetta L, DalPAsta C, et al, Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest 2004; 27:736-741, (Pubitemid 39619060)
75. Hunt PJ, Gurnell EM, Huppert FA, et al, Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000;85: 4650-4656.
76. Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005;90: 1428-1433. (Pubitemid 40463999)